Robert Douglas Bruce

Summary

Affiliation: Yale University
Country: USA

Publications

  1. ncbi Initiation, adherence, and retention in a randomized controlled trial of directly administered antiretroviral therapy
    Duncan Smith Rohrberg Maru
    Yale University AIDS Program, 135 College Street, Suite 323, New Haven, CT 06510 2283, USA
    AIDS Behav 12:284-93. 2008
  2. ncbi Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone
    R Douglas Bruce
    AIDS Program, Yale University School of Medicine, New Haven, CT, USA
    Am J Drug Alcohol Abuse 37:224-8. 2011
  3. ncbi Ethical and human rights imperatives to ensure medication-assisted treatment for opioid dependence in prisons and pre-trial detention
    R Douglas Bruce
    Yale University AIDS Program, HIV AIDS and Human Rights Program, Human Rights Watch, United States
    Int J Drug Policy 19:17-23. 2008
  4. ncbi HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine--programme description and policy implications
    R Douglas Bruce
    Yale University AIDS Program, New Haven, CT 06510 2283, United States
    Int J Drug Policy 18:326-8. 2007
  5. ncbi Case series of buprenorphine injectors in Kuala Lumpur, Malaysia
    R Douglas Bruce
    AIDS Program, Section of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut 06510 2283, USA
    Am J Drug Alcohol Abuse 34:511-7. 2008
  6. ncbi Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market
    R Douglas Bruce
    Yale University AIDS Program, New Haven, Connecticut, USA
    Am J Drug Alcohol Abuse 35:68-72. 2009
  7. ncbi Pharmacokinetic interactions between buprenorphine and antiretroviral medications
    R Douglas Bruce
    Yale University AIDS Program, New Haven, CT 06511, USA
    Clin Infect Dis 43:S216-23. 2006
  8. ncbi Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice
    R Douglas Bruce
    Yale University AIDS Program, 135 College Street, New Haven, CT 06511, USA
    J Acquir Immune Defic Syndr 41:563-72. 2006
  9. ncbi Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone
    R Douglas Bruce
    Yale University AIDS Program, 135 College Street, Suite 323, New Haven, CT, United States
    Drug Alcohol Depend 105:234-9. 2009
  10. ncbi Medication-assisted treatment and HIV/AIDS: aspects in treating HIV-infected drug users
    R Douglas Bruce
    Yale University School of Medicine, Yale University AIDS Program, 135 College Street, Suite 323, New Haven, CT 06510, USA
    AIDS 24:331-40. 2010

Research Grants

  1. Substance Abuse, HIV and HCV Treatments to Improve Health Outcomes in Drug Users
    Robert Bruce; Fiscal Year: 2007

Detail Information

Publications34

  1. ncbi Initiation, adherence, and retention in a randomized controlled trial of directly administered antiretroviral therapy
    Duncan Smith Rohrberg Maru
    Yale University AIDS Program, 135 College Street, Suite 323, New Haven, CT 06510 2283, USA
    AIDS Behav 12:284-93. 2008
    ..The presence of depression and the lack of willingness to travel greater than four blocks to receive DAART predicted time-to-discontinuation...
  2. ncbi Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone
    R Douglas Bruce
    AIDS Program, Yale University School of Medicine, New Haven, CT, USA
    Am J Drug Alcohol Abuse 37:224-8. 2011
    ..This study was conducted to characterize how tipranivir/ritonavir effects the glucuronide metabolites of BUP and may explain the reduction in the norBUP...
  3. ncbi Ethical and human rights imperatives to ensure medication-assisted treatment for opioid dependence in prisons and pre-trial detention
    R Douglas Bruce
    Yale University AIDS Program, HIV AIDS and Human Rights Program, Human Rights Watch, United States
    Int J Drug Policy 19:17-23. 2008
    ..e., do good/do no harm). Governments must take immediate action to ensure access to opioid substitution to prisoners to ensure fulfilment of ethical and human rights obligations...
  4. ncbi HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine--programme description and policy implications
    R Douglas Bruce
    Yale University AIDS Program, New Haven, CT 06510 2283, United States
    Int J Drug Policy 18:326-8. 2007
    ..Until buprenorphine maintenance therapy (BMT) was introduced, few effective strategies aimed at achieving reduction in illicit drug use were available as a conduit to anti-retroviral therapy (ARV) among IDUs...
  5. ncbi Case series of buprenorphine injectors in Kuala Lumpur, Malaysia
    R Douglas Bruce
    AIDS Program, Section of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut 06510 2283, USA
    Am J Drug Alcohol Abuse 34:511-7. 2008
    ..Prospective cohort studies, rather than hospital-derived samples, are needed to better understand the safety of buprenorphine injection...
  6. ncbi Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market
    R Douglas Bruce
    Yale University AIDS Program, New Haven, Connecticut, USA
    Am J Drug Alcohol Abuse 35:68-72. 2009
    ..To address this concern, co-formulation of buprenorphine/naloxone (BPN/NLX) replaced buprenorphine alone in Malaysia in December 2006...
  7. ncbi Pharmacokinetic interactions between buprenorphine and antiretroviral medications
    R Douglas Bruce
    Yale University AIDS Program, New Haven, CT 06511, USA
    Clin Infect Dis 43:S216-23. 2006
    ..Review of the current state of knowledge regarding specific interactions between buprenorphine and antiretrovirals is followed by a review of the clinical applicability of these interactions...
  8. ncbi Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice
    R Douglas Bruce
    Yale University AIDS Program, 135 College Street, New Haven, CT 06511, USA
    J Acquir Immune Defic Syndr 41:563-72. 2006
    ..Global access to opioid agonist therapy and HIV treatment is expanding but when concurrently used, problematic pharmacokinetic drug interactions can occur...
  9. ncbi Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone
    R Douglas Bruce
    Yale University AIDS Program, 135 College Street, Suite 323, New Haven, CT, United States
    Drug Alcohol Depend 105:234-9. 2009
    ..BUP/NLX and TPV/r should therefore be used cautiously to avoid decreased efficacy of TPV in patients taking these agents concomitantly...
  10. ncbi Medication-assisted treatment and HIV/AIDS: aspects in treating HIV-infected drug users
    R Douglas Bruce
    Yale University School of Medicine, Yale University AIDS Program, 135 College Street, Suite 323, New Haven, CT 06510, USA
    AIDS 24:331-40. 2010
    ..The current review presents an overview of issues regarding the use of medication-assisted treatments for substance abuse and dependence among HIV-infected individuals, providing medical management paradigms for their care and treatment...
  11. ncbi Case series on the safe use of buprenorphine/naloxone in individuals with acute hepatitis C infection and abnormal hepatic liver transaminases
    Robert D Bruce
    Yale University AIDS Program, New Haven, Connecticut 06511, USA
    Am J Drug Alcohol Abuse 33:869-74. 2007
    ..Previous reports in the literature have suggested hepatotoxicity with buprenorphine tempering initial enthusiasm of the safety of buprenorphine in HCV-infected patients...
  12. ncbi Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir
    Robert Douglas Bruce
    Department of Medicine, Yale University AIDS Program, New Haven, CT, USA
    J Acquir Immune Defic Syndr 54:511-4. 2010
    ..This study was conducted to examine the pharmacokinetic interactions between buprenorphine/naloxone (BUP/NLX) and lopinavir/ritonavir (LPV/r) in HIV-seronegative subjects chronically maintained on BUP/NLX...
  13. ncbi Methadone as HIV prevention: high volume methadone sites to decrease HIV incidence rates in resource limited settings
    R Douglas Bruce
    Yale University, School of Medicine, AIDS Programme, 135 College Street, Suite 323, New Haven, CT 06510, United States
    Int J Drug Policy 21:122-4. 2010
    ..To delay access to methadone only increases the probability that the individual will acquire an infectious disease that is more costly to the individual in terms of morbidity and mortality and more costly to society as a whole...
  14. ncbi Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations
    Duncan Smith Rohrberg Maru
    Yale AIDS Program, Yale University School of Medicine, New Haven, Connecticut, USA
    Clin Infect Dis 47:952-61. 2008
    ..Data are lacking on outcomes of treatment with pegylated interferon plus ribavirin (PEG-RBV) in correctional settings...
  15. ncbi Persistence of virological benefits following directly administered antiretroviral therapy among drug users: results from a randomized controlled trial
    Duncan Smith Rohrberg Maru
    Section of Infectious Diseases, AIDS Program, Yale University School of Medicine, New Haven, CT, USA
    J Acquir Immune Defic Syndr 50:176-81. 2009
    ....
  16. ncbi Initial strategies for integrating buprenorphine into HIV care settings in the United States
    Lynn E Sullivan
    Yale University School of Medicine, New Haven, CT 06520 8025, USA
    Clin Infect Dis 43:S191-6. 2006
    ....
  17. ncbi Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: implications for program replication
    Frederick L Altice
    Section of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut 06510 2283, USA
    Clin Infect Dis 38:S376-87. 2004
    ..Moreover, DAART should incorporate enhanced elements such as convenience, flexibility, confidentiality, cues and reminders, responsive pharmacy and medical services, and specialized training for staff...
  18. ncbi Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence
    Ali S Saber-Tehrani
    Yale University AIDS Program, Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, Yale University, New Haven, CT 06510, USA
    Am J Drug Alcohol Abuse 37:1-11. 2011
    ..When medication-assisted treatment for opioid dependence is concurrently used with psychotropic medications, problematic pharmacokinetic drug interactions may occur...
  19. ncbi A pilot survey of attitudes and knowledge about opioid substitution therapy for HIV-infected prisoners
    Sandra A Springer
    Yale School of Medicine, New Haven, CT, USA
    J Opioid Manag 4:81-6. 2008
    ..This study found that more education of individuals treating and caring for HIV-infected opioid dependent prisoners is needed...
  20. ncbi Adherence to hepatitis B virus vaccination at syringe exchange sites
    Frederick L Altice
    Yale University AIDS Program, 135 College Street, Suite 323, New Haven, CT 06510 2283, USA
    J Urban Health 82:151-61. 2005
    ..Trust engendered by and mutual respect afforded by such programs result in repeated encounters by active IDUs over time...
  21. ncbi Directly administered antiretroviral therapy for HIV-infected drug users does not have an impact on antiretroviral resistance: results from a randomized controlled trial
    Duncan Smith Rohrberg Maru
    Yale University AIDS Program, Yale University School of Medicine, New Haven, CT 06510 2283, USA
    J Acquir Immune Defic Syndr 46:555-63. 2007
    ..Directly administered antiretroviral therapy (DAART) is an effective intervention that improves clinical outcomes among HIV-infected drug users. Its effects on antiretroviral drug resistance, however, are unknown...
  22. ncbi Behavioral counseling content for optimizing the use of buprenorphine for treatment of opioid dependence in community-based settings: a review of the empirical evidence
    Michael M Copenhaver
    Department of Psychology, University of Connecticut, Storrs, Connecticut 06269, USA
    Am J Drug Alcohol Abuse 33:643-54. 2007
    ..Evidence points toward the use of behavioral counseling aimed at enhancing patients' motivation during treatment entry followed by an emphasis on improving coping/relapse prevention skills during the primary phase of treatment...
  23. ncbi Integration of pharmacotherapy for opioid addiction into HIV primary care for HIV/hepatitis C virus-co-infected patients
    Thomas F Kresina
    Center on AIDS and Other Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA
    AIDS 19:S221-6. 2005
    ..The integration of buprenorphine treatment for opioid addiction into HIV primary care thus provides a new treatment paradigm to address substance abuse in patients with HIV and HCV infections...
  24. ncbi Integrating care for hepatitis C virus (HCV) and primary care for HIV for injection drug users coinfected with HIV and HCV
    Thomas F Kresina
    Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, Bethesda, MD 20892, USA
    Clin Infect Dis 41:S83-8. 2005
    ..These elements, in particular treatment for substance abuse, can be focal points for model care systems that provide integrative care for both HCV and HIV infections...
  25. ncbi Models for integrating buprenorphine therapy into the primary HIV care setting
    Sanjay Basu
    AIDS Program, Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Clin Infect Dis 42:716-21. 2006
    ..The key barriers against effective integration of buprenorphine maintenance therapy and primary HIV services are discussed, and we suggest several mechanisms to overcome such obstacles...
  26. ncbi Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir
    R Douglas Bruce
    AIDS 20:783-4. 2006
  27. ncbi Impact of enhanced services on virologic outcomes in a directly administered antiretroviral therapy trial for HIV-infected drug users
    Duncan Smith-Rohrberg
    Yale University AIDS Program, New Haven, Connecticut 06510-2283, USA
    J Acquir Immune Defic Syndr 43:S48-53. 2006
    ..These results suggest the potential utility of integrating these services into DAART interventions (DAART-Plus) targeting HIV-infected drug users with problematic adherence...
  28. ncbi Pharmacological pain control for human immunodeficiency virus-infected adults with a history of drug dependence
    Sanjay Basu
    Yale University AIDS Program, Yale University School of Medicine, New Haven, CT 06511, USA
    J Subst Abuse Treat 32:399-409. 2007
    ....
  29. ncbi Clinical care of the HIV-infected drug user
    R Douglas Bruce
    Yale University AIDS Program, Yale University School of Medicine, New Haven, CT 06510, USA
    Infect Dis Clin North Am 21:149-79, ix. 2007
    ....
  30. ncbi Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services
    Laurie Sylla
    Yale University AIDS Programme, 135 College Street, Suite 323, New Haven, CT 06510, United States
    Int J Drug Policy 18:306-12. 2007
    ....
  31. ncbi Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial
    Frederick L Altice
    Yale University AIDS Program, Yale University, New Haven, CT 06510 2283, USA
    Clin Infect Dis 45:770-8. 2007
    ..Directly administered antiretroviral therapy (DAART) is one approach to improve treatment adherence among human immunodeficiency virus (HIV)-infected drug users...
  32. ncbi Editorial comment: primary care and psychosocial issues in pain
    R Douglas Bruce
    AIDS Read 17:313. 2007
  33. ncbi Clinical management of depression and anxiety in HIV-infected adults
    Sanjay Basu
    AIDS 19:2057-67. 2005
  34. ncbi Editorial comment: why treat three conditions when it is one patient?
    R Douglas Bruce
    AIDS Read 13:378-9. 2003

Research Grants2

  1. Substance Abuse, HIV and HCV Treatments to Improve Health Outcomes in Drug Users
    Robert Bruce; Fiscal Year: 2007
    ..Data used from the two phases of this study will provide an effect estimate that will be used for a R01 submission to conduct a randomized controlled trial. ..